The MHRA has disrupted two UK manufacturing facilities producing counterfeit retatrutide and tirzepatide pens, in October 2025 and February 2026
In real-world settings, additional causes of discontinuation include high out-of-pocket costs, restrictive insurance coverage, prior authorization requirements, and drug shortages [52]
Slower Phase 3 titration expected to improve tolerability
Current and pipeline incretin portfolio: GLP1, GLP1/GIP, GLP1/GRA, and amylincontaining combinations across SC and oral routes, with several Phase 23 agents aiming for ~2025% weight loss and cardiometabolic indications
Walmart offers slightly lower pricing at $920 to $950 per month
Full descriptions of the individual ingredients are not included